Quantcast

Latest Vancomycin Stories

2009-12-07 10:58:00

LAS VEGAS, Dec. 7 /PRNewswire/ -- bioMerieux, a world leader in the field of in vitro diagnostics, announced the upcoming availability of ABxAlert® from ICNet International Ltd., a global clinical informatics company, at the 44th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition. ABxAlert is a web-enabled application to help hospital clinicians ensure patients with suspected or identified microbial infections receive the optimized...

2009-11-12 07:00:00

SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it has completed enrollment in the second of two pivotal Phase 3 clinical trials evaluating the safety and efficacy of fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection, or CDI. (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO) "Completing enrollment in the second Phase 3 trial is a major milestone in the development of fidaxomicin. The two...

2009-11-03 15:15:00

SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today reported financial results for the third quarter ended September 30, 2009. Optimer reported a net loss for the third quarter of 2009 of $9.4 million, or $0.28 per share, which was in line with the Company's expectations. This compares to a net loss for the third quarter of 2008 of $9.2 million, or $0.31 per share. Research and development expenses in the third quarter of 2009 were $7.2 million,...

2009-11-01 06:15:07

A strain of MRSA that causes bloodstream infections is five times more lethal than other strains and has shown to have some resistance to the potent antibiotic drug vancomycin used to treat MRSA, according to a Henry Ford Hospital study. The study found that 50 percent of the patients infected with the strain died within 30 days compared to 11 percent of patients infected with other MRSA strains. The average 30-day mortality rate for MRSA bloodstream infections ranges from 10 percent to 30...

2009-10-29 15:13:00

EXTON, Pa., Oct. 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company will be presenting at several upcoming healthcare investment conferences. Vincent Milano, president and chief executive officer of ViroPharma, will present at the Oppenheimer 20th Annual Healthcare Conference at 4:30 P.M. EST on Tuesday, November 3, 2009. The conference is being held at the Waldorf=Astoria in New York City. Charles Rowland, vice president and chief...

2009-10-19 07:00:00

SAN DIEGO, Oct. 19 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that additional data related to fidaxomicin, the Company's lead developmental product candidate for the treatment of Clostridium difficile infection, will be presented at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) to be held at The Philadelphia Convention Center in Philadelphia, Pennsylvania October 29 through November 1, 2009. (Logo:...

2009-10-15 15:00:00

EXTON, Pa., Oct. 15 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) third quarter financial results for 2009 are expected to be released on Wednesday, October 28, 2009 before the open of the U.S. financial markets. The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2009 third quarter and other business. The press release and the live webcast of...

2009-10-13 08:36:00

BOSTON, Oct. 13 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) have awarded $5 million to an interdisciplinary group of Harvard researchers to launch the "Harvard-wide Program on Antibiotic Resistance." Headed by Michael S. Gilmore, Ph.D., (Senior Scientist, Schepens Eye Research Institute and Schepens Professor of Ophthalmology [Department of Microbiology and Molecular Genetics], HMS), the group is uniting Harvard...

2009-09-15 12:45:00

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)...

2009-09-12 13:30:00

SAN DIEGO, Sept. 12 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA. Additional data from a previously announced Phase 2 study of torezolid (TR-701) reiterate the high efficacy of...


Latest Vancomycin Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »
Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.